Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243920 | 0.73 | ACHE (0.56) | ACHEALDH1A1CYP19A1NQO2CYP3A4 | |
| SCHEMBL30835564 | 0.73 | ACHE (0.56) | ACHEALDH1A1CYP19A1NQO2CYP3A4 | |
| SCHEMBL12758265 | 0.73 | NQO2 (0.32) | NQO2MAPT | |
| SCHEMBL10459836 | 0.68 | ALDH1A1 (0.35) | ACHEALDH1A1CYP19A1KDM4EHPGD | |
| SCHEMBL8254929 | 0.67 | ACHE (0.46) | ACHEALDH1A1CYP19A1KDM4ENQO2 | |
| SCHEMBL16433700 | 0.66 | — | — | |
| SCHEMBL7778455 | 0.66 | NQO2 (0.34) | ALDH1A1KDM4EL3MBTL1NQO2 | |
| SCHEMBL9638274 | 0.66 | — | — | |
| SCHEMBL11707401 | 0.65 | ACHE (0.46) | ACHEALDH1A1CYP19A1NQO2CYP3A4 | |
| SCHEMBL22660986 | 0.65 | KDM4E (0.49) | ALDH1A1KDM4EHPGDCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915333-B1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSM IP ASSETS BV (NL) | 2015-06-03 | — | — | EP | disclosed |
| US-7601877-B2 | Condensation of a prenol or isoprenol with a hydroquinone or derivative in the presence of 0.005-1.0 mol percent of a Bronsted or Lewis acid catalyst selected from a bismuth, indium or Group 3 chloride, a heteropolyacid, and an NH- or a CH-acidic compound, oxidizing the ubihydroquinone; improved kinetics | DSM IP ASSETS B.V. (NL) | 2009-10-13 | — | — | US | disclosed |
| US-20080275275-A1 | Process for the Preparation of Ubihydroquinones and Ubiquinones | DSM IPASSETS B.V. (NL) | 2008-11-06 | — | — | US | disclosed |
| EP-1915333-A1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSMIP Assets B.V. (NL) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007017168-A1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSM IP ASSETS B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275275-A1 | Process for the Preparation of Ubihydroquinones and Ubiquinones | UBE2D3, UBE2L3, UBE2I | ACHE 2233/4885ALDH1A1 813/4885CYP19A1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.